Optimising covariate allocation at design stage using fisher information matrix for non-linear mixed effects models in pharmacometrics

• Fisher Information Matrix in nonlinear mixed effects models (NLMEM) with covariates • New computation method of Information Matrix using copula and Gaussian quadrature • Optimisation of covariate allocation using partitioning and projected gradient • Reduced sample size needed to detect clinically relevant covariate in a PK example A novel framework is introduced to design experiments for pharmacometrics studies analysed by Non-Linear Mixed Effects Models (NLMEM) including covariates to describe inter-individual variability. Covariate effects may help identify subpopulations at risk of sub-therapeutic or toxic responses, for instance when hepatic or renal impairment reduces drug elimination, increasing safety risks. Before collecting and modelling new clinical trial data, choosing an appropriate design is crucial, particularly to ensure sufficient information to estimate covariate effects and their uncertainty. Assuming a known NLMEM with covariate effects and a joint distribution for covariates in the target population from previous clinical studies, the proposed approach optimises the allocation of covariates among the subjects to be included in a new trial. It aims achieving better overall parameter estimations and therefore increase power of statistical tests on covariate effects to detect the clinical relevance or non-relevance of relationships. The methodology relies on the Fisher Information Matrix and introduces a fast and deterministic computation method, leveraging Gaussian quadrature and copula modelling. The domains of continuous covariates were divided into clinically meaningful intervals and their proportions optimised, along with the proportion of each category for the discrete covariates. The optimisation problem was formulated as a convex problem subject to linear constraints, allowing resolution using Projected Gradient Descent algorithm. Different scenarios for a pharmacokinetics model including either biological measurements of renal or hepatic function as covariate were explored. Covariate optimisation was shown to reduce the number of subjects needed to achieve desired power in covariate tests for relevance or non-relevance.